FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The study is conducted as a monocentric prospective phase II trial. Patients with
unresectable stage III locally advanced pancreatic cancer (defined for extended encasement of
superior mesenteric artery/celiac axis/hepatic artery or for combined venous and arterial
involvement or for unreconstructible venous encasement), ECOG PS 0-1 and age 18-75 are
eligible.
After multidisciplinary evaluation of resectability, treatment with FOLFOXIRI is provided for
a maximum of 12 cycles with multidisciplinary evaluation of disease status every 4 cycle.
In case of tumors have deemed resectable surgery is considered. In case tumors remain
unresectable, radiotherapy is evaluated after the end of chemotherapy.
Primary objective of the study is the rate of patients who become resectable and undergo
radical surgical resection after chemotherapy.
Secondary objectives are: response rate, progression-free survival, overall survival,
toxicity.